bioRxivImmunologyPreprint
In vivo CRISPR screening identifies Fli1 as a transcriptional safeguard that restrains effector CD8 T cell differentiation during infection and cancer
Z. Chen, E. Arai, O. Khan, Z. Zhang, S. F. Ngiow, Y. He, H. Huang, S. Manne, Z. Cao, A. E. Baxter, Z. Cai, E. Freilich, M. A. Ali, J. R. Giles, J. E. Wu, A. R. Greenplate, M. Kurachi, K. Nzingha, V. Ekshyyan, Z. Wen, N. A. Speck, A. Battle, S. L. Berger, E. J. Wherry, J. Shi
Abstract
Improving effector activity of antigen specific T cells is a major goal in cancer immunotherapy. Despite the identification of several effector T cell (TEFF)-driving transcription factors (TF), the transcriptional coordination of TEFF biology remains poorly understood. We developed an in vivo T cell CRISPR screening platform and identified a novel mechanism restraining TEFF biology through the ETS family TF, Fli1. Genetic deletion of Fli1 enhanced TEFF responses without compromising memory or exhaustion precursors. Fli1 restrained TEFF lineage differentiation by binding to cis-regulatory elements of effector-associated genes. Loss of Fli1 increased chromatin accessibility at ETS:RUNX motifs allowing more efficient Runx3-driven TEFF biology. CD8 T cells lacking Fli1 provided substantially better protection against multiple infections and tumors. These data indicate that Fli1 safeguards the developing CD8 T cell transcriptional landscape from excessive ETS:RUNX-driven TEFF cell differentiation. Moreover, genetic deletion of Fli1 improves TEFF differentiation and protective immunity in infections and cancer.
- organism: mouse
- assay: bulk RNA-seq
- assay: ChIP-seq
- research focus: cell type annotation
- research focus: gene regulatory network inference
- research focus: drug response / drug discovery
- approach: genetic perturbation / CRISPR
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Discovery of Tcf7 regulators with clonally-resolved CRISPR screens identifies Trim28 as a mediator of CD8 T cell differentiation in tumors
Marc A. Schwartz, Dillon Lue, … Nir Hacohen·bioRxiv·Jun 17, 2026
- Pre-division TCF1 drop determines long-term CD8 T cell fates
Natalie R. Favret, Maider Astorkia, … Mary Philip·bioRxiv·Oct 6, 2025
- Gfi1 controls the formation of effector CD8 T cells during chronic infection and cancer
Oluwagbemiga A. Ojo, Hongxing Shen, … Lewis Z. Shi·Nature CommunicationsPeer-reviewed·May 15, 2025
- TCF-7 is dispensable for the anti-tumor response but required for the persistent function of mature CD8 T cells
R. Harris, M. Mammadli, … M. Karimi·bioRxiv·Mar 22, 2021
- A TAK1Cytokine Toxicity Checkpoint Controls Anti-Cancer Immunity
Tirta Mario Djajawi, Anne Huber, … Conor J. Kearney·bioRxiv·May 9, 2025
- Atlas-Guided Discovery of Transcription Factors for T Cell Programming
H. K. Chung, C. Liu, … S. M. Kaech·bioRxiv·Jan 3, 2023